Unaudited Interim Report

Nuformix PLC

22 May 2023

 

Nuformix plc

("Nuformix", the "Company" or the "Group")

Unaudited Interim Report

22 May 2023: Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces its unaudited results for the twelve months ended 31 March 2023 following the change in the Company's accounting reference date from 31 March to 30 September.

Operational highlights

·    The Company successfully conducted studies in state-of-the-art 3D human Idiopathic Pulmonary Fibrosis ("IPF") lung tissue, using a disease and species relevant model, which initially focused on the anti-fibrotic action of NXP002 in combination with current standards-of-care ("SoC"). The results indicated:

o  NXP002 alone delivered a strong, consistent anti-fibrotic effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis; and

o  Both high and low concentrations of NXP002 showed an additive anti-fibrotic effect to SoC.

·    The anti-inflammatory action of NXP002 was subsequently investigated, post period end, in the same model and the results indicated:

o  NXP002 alone delivered a strong, consistent anti-inflammatory effect as demonstrated by modulation of the release of multiple biomarkers of inflammation; and

o  NXP002 increased the performance of SoCs in modulating the release of a panel of inflammation biomarkers associated with the progression of fibrotic lung disease.

·    The Company additionally successfully conducted duration of action studies using an exploratory 3D human lung tissue model offering species relevance and NXP002 dosage control. This allowed investigation of NXP002's anti-inflammatory action at various timepoints following challenge with lipopolysaccharide ("LPS"), a stimulant that induces measurable endpoints and pathways relevant to IPF progression. The results indicated:

o  NXP002 suppresses the release of inflammatory cytokines by healthy human lung tissue following LPS challenge; and

o  A strong anti-inflammatory effect remains at 12 hours post drug dosing demonstrated by continued suppression of the release of inflammatory cytokines following LPS challenge, confirming NXP002 has a suitable duration of action to support its Target Product Profile of twice daily dosing.

·    In vitro dissolution comparisons of NXP004 co-crystals to Lynparza® (commercially available olaparib) demonstrated that the two lead NXP004 cocrystals selected out-perform Lynparza®, in terms of rate and extent of dissolution and release of olaparib.

Financial Highlights for the twelve months ended 31 March 2023

·    Loss before tax £761,299 (31 March 2022: loss of £1,270,273).

·    Loss on ordinary activities (after tax credit) of £760,136 (31 March 2022: loss of £1,108,994).

·    Loss per share 0.11p (31 March 2022: loss per share 0.19p).

·    Net assets of £4,228,204 (31 March 2022: £4,737,961) including £259,259 of cash and cash equivalents at 31 March 2023 (31 March 2022: £464,095).

·    The Company's accounting reference date and financial year end was changed from 31 March to 30 September.

·      Post period end, on 13 April 2023, a subscription for 35,000,000 new ordinary shares at a price of 0.20 pence per share raised gross proceeds of £70,000. The subscription was undertaken with a single UK-based FCA regulated institutional investor. In addition, the participant in the subscription was issued with one warrant for every one new ordinary share subscribed for with an exercise price of 0.25 pence per warrant. These warrants could result in the issue of an additional 35,000,000 new ordinary shares raising a further £87,500 for progression of the Company's business activities. 

Dr Dan Gooding, Executive Director of Nuformix, said: "Our interim report demonstrates the Company is continuing to generate value-adding data for its lead programmes whilst further optimising its operational costs. For NXP002, our pre-clinical strategy has delivered consistently positive results that allow us to tell a complete pre-clinical story to potential licensing partners for the first time and demonstrate that inhaled treatment of IPF via NXP002 is a viable concept. Our near-term goals focus on our NXP002 programme, as we continue to generate robust data to support our out-licensing objectives, all achievable using existing funds thanks to our lean operational model which will continue to operate. We are greatly encouraged by our recent work in close-to-patient human tissue models, in particular the new data supporting NXP002's duration of action and Target Product Profile. I am excited by our prospects for the remainder of the year as we formally commence partnering activities and look forward to sharing results as they emerge."

Enquiries:

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information, please visit www.nuformix.com.

Chairman's statement

Following the change of the Company's accounting reference date from 31 March to 30 September these interim results cover the 12 month period to 31 March 2023. The Company's interim results for the six month period ended 30 September 2022 were announced on 13 December 2022 and the operational review below covers the subsequent period from 30 September 2022 to 31 March 2023, a period of further progress for the Company's assets NXP002 and NXP004.

Operational review

NXP002 (new form of tranilast) - Idiopathic Pulmonary Fibrosis (IPF)

NXP002 is the Group's pre-clinical lead asset and a potential novel inhaled treatment for IPF and possibly other fibrosing interstitial lung diseases ("ILDs"). It is a proprietary, new form of the drug tranilast, to be delivered in an inhaled formulation.

IPF is a devastating lung disease associated with a higher mortality rate than many cancers. Thus, IPF represents a high unmet medical need such that the requirement for improved treatment options represents a significant commercial opportunity. IPF is classified as a rare disease and presents a global commercial market that is forecast to grow to US$8.8bn by 2027. Sales of standard-of-care therapies OFEV and Esbriet achieved US$2.5bn and US$1bn respectively in 2021.

Tranilast has a long history of safe use as an oral drug for asthma, keloids and hypertrophic scarring, but there is growing evidence that supports its potential in other fibrotic conditions, including IPF. NXP002 is differentiated as it is a patent protected new form of tranilast that has been enabled for formulation and delivery direct to the lungs by inhalation, a new route of administration for this drug. The inhalation route is a well-known strategy for treatment of lung diseases to yield greater efficacy and reduce systemic side-effects compared to oral treatment. Discontinuation rates for standard-of-care IPF therapies can be as high as 80% in certain patient groups due to systemic side-effects. Effective inhalation therapies offer the potential to overcome these limitations of oral therapies. Nuformix has two patent families protecting new forms of tranilast, both of which have already been granted in major pharmaceutical territories, with patent prosecution progressing in additional territories of interest. In addition, in March 2022, a method of use patent application was filed specific to IPF treatment.

As a potential treatment for IPF, which is a rare disease, NXP002 is a likely candidate for Orphan Drug Designation, which could provide additional product protection against potential competitors. The positioning of NXP002 as an inhaled treatment for IPF could be either as added to SoC's or administered as a monotherapy for patients non-responsive to SoCs and those declining these therapies due to side effects which impact quality of life.

The pre-clinical inhalation strategy, initiated by the Company has significantly progressed NXP002 demonstrating:

·      it can be delivered in-vivo by a range of nebulisers at the optimum particle size for delivery to the deep lung;

·      very high doses appear to be well-tolerated; and

·      an in-vivo inhalation dose response was observed for inflammatory and fibrotic biomarkers that is consistent with all ex-vivo human IPF tissue studies to date.

The Company conducted studies in a new iteration of a 3D human IPF lung tissue using a disease and species relevant model that has been advanced to significantly reduce output variability. The results from these studies of NXP002 alone and in combination with current standards of care ("SoC"), can be summarised as follows:

·    NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events;

·    NXP002 alone delivers a strong, consistent anti-fibrotic and anti-inflammatory effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis and inflammation;

·    both high and low concentrations of NXP002 show an additive anti-fibrotic and anti-inflammatory effect to SoC;

·    in particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis biomarker release, yet at lower concentrations than have been seen in other pre-clinical models to date; and

·    the clear, pronounced additive benefit of NXP002 on top of SoCs observed suggests that NXP002 will provide additional efficacy, even in patients responding to SoC therapy. This raises the possibility that NXP002 targets additional disease pathways to SoC's when increasing the combined anti-fibrotic and anti-inflammatory response.

As announced on 18 May 2023, following success in suppressing biomarkers of fibrotic disease progression in human IPF lung tissue, the same samples were analysed to assess additional mechanistic and anti-inflammatory benefits on top of SoC's and the results are summarised as follows:

·      NXP002 alone delivers a strong, consistent anti-inflammatory effect as demonstrated by suppression of the release of inflammatory cytokines by over 90% for all cytokines studied; and

·      the results further suggests that NXP002 will provide additional efficacy in combination with SoC's, even in patients responding to SoC therapy alone.

Nuformix has developed a Target Product Profile that is consistent with twice daily inhalation administration. To assess NXP002's duration of action in relation to the Target Product Profile, the Company initiated work in an exploratory model in healthy human lung tissue. The model also bridges the Company's successful pre-clinical work across a variety of LPS-challenge studies. The results are summarised as follows:

·      NXP002 suppresses the release of inflammatory cytokines by healthy human lung tissue following LPS challenge; and

·      a strong anti-inflammatory effect remains at 12 hours post drug dosing demonstrated by continued suppression of the release of inflammatory cytokines following LPS challenge, confirming NXP002 has a suitable duration of action to support its Target Product Profile of twice daily dosing.

Overall, the results further strengthen NXP002's potential for development as a new inhaled treatment for IPF either in addition to existing therapies or as a monotherapy. The Board continues to be encouraged by the progress of the studies and the positive data generated to date, in particular the recent duration of action study results and is focused on next steps which include:

·    expansion of the current studies to include further human IPF tissue donors to demonstrate the robustness of NXP002's anti-fibrotic response alone and in SoC combinations; and

·    formally commencing the NXP002 partnering process.

NXP004 (novel forms of olaparib) - Oncology

The Group discovered novel forms of olaparib, a drug currently marketed by AstraZeneca, a Lynparza®. Lynparza® was first approved in December 2014 for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation. Since then, it has secured similar approvals in breast, pancreatic and prostate cancers with further trials on-going. These approvals have propelled Lynparza® sales to US$2.7bn in 2021 with industry analysts forecasting annual sales of US$9.7bn by 2028.

The Group has filed two patent applications on its novel forms of olaparib with the potential for patent life to 2040/2041.

The Company demonstrated enhanced performance of NXP004 cocrystals compared to olaparib. Subsequently, further preformulation studies allowed the Company to identify lead cocrystals to be progressed for further development.

Results from in vitro dissolution studies demonstrated that the two lead NXP004 cocrystals out-performed Lynparza®, both in terms of rate and extent of dissolution and release of olaparib.

Enhancement of dissolution in the currently marketed formulation of Lynparza® resulted in improved bioavailability versus the initial marketed product. Therefore, the NXP004 programme may offer potential to further increase olaparib bioavailability. In addition, the potential simplicity of NXP004-based formulations may offer improvements in product cost-of-goods versus the currently marketed product, which requires complex manufacturing methods.

These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic products.

The Company will now consider the design and execution of suitable pre-clinical pharmacokinetic models to further investigate and validate NXP004's potential for enhancing the oral absorption of olaparib. Securing these data will enable commencement of discussions with multiple potential commercialisation partners.

This work will direct and support future out-licensing discussions for NXP004.

NXP001 (new form of aprepitant) - Oncology

NXP001 is a proprietary new form of the drug aprepitant that is currently marketed as a product in the oncology supportive care setting (chemotherapy induced nausea and vomiting). Nuformix granted an exclusive license to Oxilio Ltd ("Oxilio"), a privately held pharmaceutical development company, to license NXP001 globally for oncology indications on terms previously disclosed. A programme of formulation development was defined. Significant progress has been made exploring numerous formulation adaptations. This work is detailed, time consuming and ongoing. Despite Covid related supply chain issues Oxilio have generated more cocrystal supplies to allow this work to continue.

Fundraising

Post period end, on 13 April 2023, the Company completed a subscription to raise gross proceeds of £70,000 through a subscription for 35,000,000 new ordinary shares of 0.1 pence in the capital of the Company (the "New Ordinary Shares") at a price of 0.20 pence per share (the "Subscription").  The Subscription was undertaken with a single  UK-based FCA regulated institutional investor. The New Ordinary Shares represent approximately 4.7 per cent. of the Company's enlarged issued share capital. 

In addition, the participant in the Subscription was issued with one warrant for every one New Ordinary Share subscribed for with an exercise price of 0.25 pence per warrant. These warrants will be exercisable for two years from Admission ("Warrants"). If the Warrants are exercised in full, it would result in the issue of an additional 35,000,000 new ordinary shares raising a further £87,500 for progression of the Company's business activities. The New Ordinary Shares and Warrants were issued pursuant to the Company's existing share issuance authorities.

The net proceeds of the Subscription will be used by the Company primarily to further advance its NXP002 programme for the inhaled treatment of IPF.

Outlook

The Company to continues to advance and exploit the current assets within the portfolio through the R&D and business development activities as set out above. The sharing agreement with Lanstead provides cash on a monthly basis until October 2023 to the Company to fund its lean operations and together with the funds raised in the April 2023 Subscription will provide the Company with sufficient financial resources until any such time that the Group's R&D and targeted partnering activities require further resource.

The strategy of the Group is to continue to increase the value of its existing assets while maintaining tight control of costs, including conducting business development/licensing activities using a structured and data-driven approach, with the goal of seeking global licensing deals.

Financial Review

In the period, the Board has continued to focus expenditure on R&D activities that add value to the current assets while optimising the operation to minimise administrative expenditure and the operational cost-base.

Dr Julian Gilbert

Non-Executive Chairman

22 May 2023

Statement of Directors' Responsibilities

We confirm that to the best of our knowledge:

1.    this interim condensed set of financial statements has been prepared in accordance with UK adopted IAS 34 'Interim Financial Reporting';

2.    the condensed set of financial statements has been prepared in accordance with ASB's 2007 Statement Half-Yearly Reports;

3.    the condensed set of financial statements give a true and fair view of the asset, liabilities, financial position and profit or loss of the group and the undertakings included in the consolidation as a whole as required by DTR 4.2.4R; and

4.    the interim management report includes a fair review of the information required by:

4.1.  DTR 4.2.7R of the Disclosure Guidance and Transparency Rules, being an indication of important events that have occurred during the first six months of the financial year and their impact on the condensed set of financial statements; and a description of the principal risks and uncertainties for the remaining six months of the year; and

4.2.  DTR 4.2.8R of the Disclosure Guidance and Transparency Rules, being related party transactions that have taken place in the first six months of the current financial year and that have materially affected the financial position or performance of the entity during that period; and any changes in the related party transactions described in the last annual report that could do so.

The directors of Nuformix plc are listed in the Group's 2022 Annual Report and Accounts and the current board are set out on the Investors Information section of Nuformix's website at: Investors Information - Nuformix

Dr Julian Gilbert

Non-Executive Chairman

22 May 2023

Further copies of this document are available from the company's registered address and will be available on the company's website later today.

Nuformix plc

Registration number: 09632100

Nuformix plc

Registration number: 09632100

Unaudited Interim Results

Consolidated Income Statement

and Statement of Comprehensive Income for the twelve months ended 31 March 2023

		12 months ending 31 March	12 months ending 31 March
		2023	2022
		Unaudited	Audited
	Note	£	£
Revenue		-	50,000
Cost of sales		-	(1,695)
Gross profit		-	48,305
Total administrative expenses		(761,299)	(1,318,577)
Other operating income		-	-
Operating loss		(761,299)	(1,270,272)
Finance costs		-	-
Loss before tax		(761,299)	(1,270,272)
Income tax receipt		1,163	161,279
Loss for the period and total comprehensive income for the period		(760,136)	(1,108,993)
Loss per share - basic and diluted	4	0.11p	0.19p

Nuformix plc

Registration number: 09632100

Unaudited Interim Results

Consolidated Statement of Financial Position as at 31 March 2023

		31 March	31 March
		2023	2022
	Note	Unaudited	Audited
		£	£
Assets
Non-current assets
Property, plant and equipment	5	-	438
Intangible assets	6	4,113,953	4,150,411
		4,113,953	4,150,849
Current assets
Trade and other receivables		128,547	199,600
Income tax asset		-	161,279
Cash and cash equivalents		259,259	464,095
		387,806	824,974
Total assets		4,501,759	4,975,823
Equity and liabilities
Equity
Share capital	7	709,309	615,609
Share premium		6,635,378	6,500,817
Merger relief reserve		10,950,000	10,950,000
Reverse acquisition reserve		(8,005,195)	(8,005,195)
Share option reserve		2,048,781	2,026,664
Retained earnings		(8,110,069)	(7,349,933)
Total equity		4,228,204	4,737,962
Current liabilities
Trade and other payables		273,555	237,861
		273,555	237,861
Total equity and liabilities		4,501,759	4,975,823

 

Nuformix plc

Unaudited Interim Results

Consolidated Statement of Changes in Equity for the twelve months ended 31 March 2023

	Share capital £	Share premium £	Merger Relief Reserve £	Reverse acquisition reserve	Share option reserve	Retained earnings £	Total £
At 31 March 2021	591,609	6,384,835	10,950,000	(8,005,195)	2,005,952	(6,240,940)	5,686,261
Loss for the half-year and total comprehensive loss	-	-	-	-	-	(1,108,993)	(1,108,993)
Issue of share capital	24,000	145,982	-	-	-	-	169,982
Share issue costs	-	(30,000)	-	-	-	-	(30,000)
Share and warrant based payment	-	-	-	-	20,712	-	20,712
At 31 March 2022	615,609	6,500,817	10,950,000	(8,005,195)	2,026,664	(7,349,933)	4,737,962
Loss for the half-year and total comprehensive income	-	-	-	-	-	(760,136)	(760,136)
Issue of share capital	-	134,561	-	-	-	-	134,561
Share and warrant based payment	-	-	-	-	22,117	-	22,117
As at 31 March 2023	709,309	6,635,378	10,950,000	(8,005,195)	2,048,781	(8,110,069)	4,228,204

Nuformix plc

Unaudited Interim Results

Consolidated Statement of Cash Flows for the twelve months ended 31 March 2023

	12 months ending 31 March	Year Ended 31 March
	2023	2022
	Unaudited	Audited
	£	£
Cash flows from operating activities
Loss for the year	(760,136)	(1,108,993)
Adjustments to cash flows from non-cash items
Depreciation and amortisation	36,895	36,976
Income tax expense	-	(161,279)
Share and warrant based payment	22,117	20,712
	(701,124)	(1,212,584)
Working capital adjustments
(Increase) decrease in trade and other receivables	69,891	(167,340)
Increase (decrease) in trade and other payables	35,694	(86,763)
Cash generated from operations	105,585	(254,103)
Income taxes (paid)/received	162,442	121,020
Net cash flow from operating activities	(433,097)	(1,345,667)
Cash flows from investing activities
Net cash flows from investing activities	-	-
Cash flows from financing activities
Proceeds of share issue	228,261	139,982
Net cash flows from financing activities	228,261	139,982
Net (decrease)/increase in cash and cash equivalents	(204,836)	(1,205,685)
Cash and cash equivalents at start of period	464,095	1,669,780
Cash and cash equivalents at end of period	259,259	464,095

Nuformix plc

Unaudited Interim Results

Notes to the Consolidated Financial Statements for the twelve months ended 31 March 2023

1. Basis of preparation of interim financial information

The consolidated interim financial statements have been prepared in accordance with the recognition and measurement principles of International Accounting Standards as endorsed by the UK Endorsement Board ("IAS"), and are compliant with IAS34 "Interim Financial Reporting".

The Group prepares its accounts in accordance with applicable UK Adopted International Accounting Standards.

The accounting policies and methods of computation followed in the condensed consolidated interim financial statements are the same as those applied in the most recent annual report.

The consolidated interim financial statements are unaudited and do not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 March 2022, prepared in accordance with IAS, have been filed with the Registrar of Companies. The Auditors' Report on these accounts was unqualified and included a reference to which the Auditors drew attention by way of an emphasis of matter, without qualifying their report, that a material uncertainty existed that might cast significant doubt on the Group's ability to continue as a going concern at that time. The Auditors' Report did not contain any statements under section 498 of the Companies Act 2006.

The condensed consolidated interim financial statements are for the 12 months to 31 March 2023.

The condensed consolidated interim financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the group's annual financial statements for the year ended 31 March 2022, which were prepared in accordance with UK adopted International Accounting Standards ("IFRSs").  As explained above, although this was a different accounting framework, there is no impact on recognition, measurement or disclosure. 

2. Basis of consolidation

On 16 October 2017 the Company acquired the entire issued ordinary share capital of Nuformix Technologies Limited and became the legal parent of Nuformix Technologies Limited. The accounting policy adopted by the Directors applies the principles of IFRS 3 (Revised) "Business Combinations" in identifying the accounting parent as Nuformix Technologies Limited and the presentation of the Group consolidated statements of the Company (the legal parent) as a continuation of financial statements of the accounting parent or legal subsidiary (Nuformix Technologies Limited).

3. Going concern

The consolidated interim financial statements have been prepared on the going concern basis of preparation which, inter alia, is based on the directors' reasonable expectation that the Group has adequate resources to continue to operate as a going concern for at least twelve months from the date of their approval. In forming this assessment, the directors have prepared cashflow forecasts covering the period ending 31 March 2024 which take into account the likely run rate on overheads and planned research expenditure.

Whilst there can be no guarantee of the successful outcome of future studies, in compiling the cashflow forecasts the directors have made cautious estimates of the likely outcome of such studies, when a fundraise may complete and have considered alternative strategies should projected funding be delayed or fail to materialise. These strategies include postponing non-committed research expenditure, securing alternative licensing arrangements from those currently planned and additional corporate activity to support the business.

These circumstances indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern.  The consolidated interim financial statements do not include any adjustments that would result if the company or Group was unable to continue as a going concern.

After careful consideration, the directors consider that they have reasonable grounds to believe that the Group can be regarded as a going concern and, for this reason, they continue to adopt the going concern basis in preparing the consolidated interim financial statements.

4 Loss per Share

Loss per share is calculated by dividing the loss after tax attributable to the equity holders of the Group by the weighted average number of shares in issue during the period.

The basic earnings per share for each comparative period is calculated by dividing the loss in each of those periods by the legal entity's historical weighted average number of shares outstanding.

	31 March	31 March
	2023 Unaudited £	2022 Audited £
Loss after tax	(760,136)	(1,108,993)
Weighted average number of shares	708,282,519	598,447,724
Basic and diluted loss per share	0.11p	0.19p

5 Property, Plant and Equipment	Computer equipment	Total
	£	£
Cost or valuation
At 31 March 2021	1,561	1,561
At 31 March 2022	1,561	1,561
At 31 March 2023	1,561	1,561
Depreciation
At 31 March 2021	604	604
Charge	519	519
At 31 March 2022	1,123	1,123
Charge	438	438
At 31 March 2023	1,561	1,561
Carrying amount
At 31 March 2021	957	957
At 31 March 2022	438	438
At 31 March 2023	-	-

6 Intangible Assets		Goodwill		Patents	Total
Cost		£		£	£
At 31 March 2021			4,023,484	449,611	4,473,095
Written Off			-	(85,035)	(85,035)
At 31 March 2022			4,023,484	364,576	4,388,060
At 31 March 2023			4,023,484	364,576	4,388,060
Amortisation
At 31 March 2021			-	286,227	286,227
Charge			-	36,457	36,457
On Written Off			-	(85,035)	(85,035)
At 31 March 2022			-	237,649	237,649
Charge			-	36,458	36,458
At 31 March 2023			-	274,107	274,107
At 31 March 2021			4,023,484	163,384	4,186,868
At 31 March 2022			4,023,484	126,927	4,150,411
At 31 March 2023			4,023,484	90,469	4,113,953

For impairment testing purposes, management consider the operations of the Group to represent a single cash-generating unit ("CGU") focused on research and development. Consequently, the goodwill is effectively allocated and considered for impairment against the business as a whole being the single CGU.

7 Share Capital

Allotted, called up and fully paid shares

	31 March 2023 Unaudited		31 March 2022 Audited
	No.	£	No.	£
Ordinary shares of £0.001 each	709,309,368	709,309	615,609,368	615,609

In December 2021 the Company entered into a Sharing Agreement with Lanstead, split into two tranches of new shares issued with payments to be received over a 20-month period from March 2022 to October 2023.

The agreement is structured in such a way that the proceeds received by the Company are linked to the market price for the Company's shares. The proceeds are calculated based on the volume-weighted average share price in the month preceding the payment from Lanstead, compared to a benchmark price of 2p per share. Based on historic share prices, and a valuation as at the latest available price the total proceeds from Tranche 2 (issued in April 2022) are expected to be £228,261 (including Share Premium of £34,561), of which £87,087 has been recognised in debtors.

8 Share Options and Warrants

The Group operates share-based payments arrangements to remunerate directors and key employees in the form of a share option scheme. Equity-settled share-based payments are measured at fair value (excluding the effect of non-market-based vesting conditions) at the date of grant. The fair value determined at the grant date of the equity-settled, share-based payments and is expensed on a straight-line basis over the vesting period, based on the Group's estimate of shares that will eventually vest and adjusted for the effect of non-market based vesting conditions.

 

END